NCT04419389 - APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 2, 2021

Primary Completion Date

August 23, 2021

Study Completion Date

August 24, 2021

Conditions

Non Hodgkin LymphomaChronic Lymphocytic LeukemiaMantle Cell Lymphoma

Interventions

DRUG

APR-246 (eprenetapopt) + Acalabrutinib in CLL

APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)

DRUG

APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL

APR-246 D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule (APR 246 Monotherapy Lead-in; 4.5 g/d x 2)

DRUG

APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT

APR-246 D1, 8 and 15 of each cycle Acalabrutinib will be given at a standard dose and schedule Venetoclax and Rituxiab will be given at a standard dose and schedule

DRUG

APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT

APR-246 4.5 g/d D1, 8 and 15 of each cycle Venetoclax + Rituximab will be given at a standard dose and schedule

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

77030

MD Anderson Cancer Center, Houston

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston